Sign In
Buy CASI
$0.208
+0 (+0%)
At Close: May 22, 2026
Siga Technologies (NASDAQ:SIGA) and CASI Pharmaceuticals (NASDAQ:CASI) Financial Comparison
04:43am, Sunday, 29'th Mar 2026
CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) and Siga Technologies (NASDAQ: SIGA - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast
What Drove CASI Pharmaceuticals' 24% Rise After Hours?
03:02am, Thursday, 26'th Feb 2026
CASI Pharmaceuticals shares surged over 24% after hours to $0.28 despite a formal Nasdaq delisting and plans to transition to OTC Markets.
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
09:00am, Wednesday, 25'th Feb 2026
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope AMR is a leading cause of kidney transplant loss with no approved treatments U.S. IND previously appro
Additional proof of concept data consistent and strengthen data set shared at ASH 2025 Management to host meetings at JP Morgan 44th Annual Healthcare Conference 2026 SAN FRANCISCO, CALIFORNIA / ACCES
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
04:05pm, Tuesday, 23'rd Dec 2025
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
09:00am, Thursday, 11'th Dec 2025
- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc. (NAS
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-cl
CASI Pharmaceuticals Announces Changes in Board Governance
09:00am, Wednesday, 19'th Nov 2025
James Huang appointed as Non-Executive Chairman of CASI Board of Directors SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 19, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
04:05pm, Friday, 14'th Nov 2025
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on the development of CID-103, a potential
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
04:05pm, Monday, 10'th Nov 2025
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
09:00am, Tuesday, 04'th Nov 2025
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential b
- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody - Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / No
CASI Pharmaceuticals Appoints James Huang to Board of Directors
09:45am, Friday, 26'th Sep 2025
- Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) S
- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody - Safety profile observed in first four dose cohorts supports continued development - No serious adverse events or
